Theravance BiopharmaTBPH
About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Employees: 99
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
211% more call options, than puts
Call options by funds: $118K | Put options by funds: $38K
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
10% more funds holding
Funds holding: 120 [Q1] → 132 (+12) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
3.58% less ownership
Funds ownership: 100.45% [Q1] → 96.88% (-3.58%) [Q2]
8% less capital invested
Capital invested by funds: $434M [Q1] → $400M (-$34.7M) [Q2]
11% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 47
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Douglas Tsao 53% 1-year accuracy 54 / 102 met price target | 75%upside $15 | Buy Reiterated | 16 Sept 2024 |
HC Wainwright & Co. Douglas Tsao 53% 1-year accuracy 54 / 102 met price target | 75%upside $15 | Buy Maintained | 6 Aug 2024 |
TD Cowen Marc Frahm 100% 1-year accuracy 1 / 1 met price target | 5%upside $9 | Hold Maintained | 6 Aug 2024 |
Leerink Partners David Risinger 100% 1-year accuracy 4 / 4 met price target | 16%upside $10 | Market Perform Downgraded | 6 Aug 2024 |
